World Federation of Hemophilia / Fédération mondiale de l'hémophilie/LinkedIn
Oct 18, 2025, 11:15
Gene Therapy Data at Risk – WFH Advocates for Global Preservation Through GTR
World Federation of Hemophilia / Fédération mondiale de l’hémophilie posted on LinkedIn:
” Nearly 400 people with hemophilia joined Gene Therapy trials, sharing their data to help future generations. If companies do not commit to preserve Gene Therapy data in one global database, that data becomes far less useful. The WFH Gene Therapy Registry (GTR) offers a global solution to safeguard this data and honor those contributions.
Read more about why data preservation is both a scientific and ethical imperative.”

Stay updated with Hemostasis Today.
-
Nov 18, 2026, 14:29Maxime Dely: When Patient Encounters Become Life Lessons
-
Nov 18, 2026, 14:23Basanta Khatiwada: Advancing Haematology Through Research and Innovation at HAEMATOCON 2026
-
Nov 18, 2026, 14:13Alvin Katumba: Sickle Cell Disease Research Recognised With a 2026 ASH Abstract Achievement Award
-
Nov 18, 2026, 13:34Vincenzo De Angelis: Strengthening Plasma Management and Quality Control in Eastern Europe
-
Nov 18, 2026, 13:34Standardizing Bleeding Outcome Assessment in Hemophilia Clinical Trials – JTH
-
Nov 18, 2026, 13:34Nicolas Gendron: Towards Sustainable Anticoagulation
-
Nov 18, 2026, 13:33Breaking the Silence on Women and Girls with Bleeding Disorders – EHC
-
Nov 18, 2026, 13:32Maria Elisa Mancuso: Next-Generation Protein Therapies in Hemophilia
-
Nov 18, 2026, 13:25Maia Meier: Advocating for Women and Girls with Bleeding Disorders